Evidence map›Paper›PMID 41877607›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2026

State AIDS Drug Assistance Programs' Contribution to the US Viral Suppression, 2015-2022.

Kathleen A McManus, Amy Killelea, Erin Q Rogers, Feng Liu, Tim Horn, Amber Steen, Jessica Keim-Malpass, Auntré Hamp, Elizabeth T Rogawski McQuade

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Kathleen A McManusDivision of Infectious Diseases and International Health, University of Virginia School of Medicine, Charlottesville, Virginia, USA.ORCID 0000-0001-5786-0018
Amy KilleleaDivision of Infectious Diseases and International Health, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
Erin Q RogersDivision of Infectious Diseases and International Health, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
Feng LiuDivision of Infectious Diseases and International Health, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
Tim HornNASTAD, Washington, District of Columbia, USA.
Amber SteenSchool of Nursing, University of Virginia, Charlottesville, Virginia, USA.ORCID 0009-0008-9258-0132
Jessica Keim-MalpassDivision of Pediatric Hematology/Oncology, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
Auntré HampNASTAD, Washington, District of Columbia, USA.
Elizabeth T Rogawski McQuadeRollins School of Public Health, Emory University, Atlanta, Georgia, USA.ORCID 0000-0002-4942-3747

Funding

Viral Suppression for People with HIV with Low Incomes: Study of Disparities, Health Equity, and Best PracticesR01AI170093 · NIAID · UNIVERSITY OF VIRGINIA · PI Kathleen Ann McManus · 2023 to 2026
$2.9M
National Institute of Allergy and Infectious DiseasesNIAID NIH HHS R01 AI170093NIH HHS R01AI170093
6 · The paper itself

Abstract

backgroundState AIDS Drug Assistance Programs (ADAPs) provide human immunodeficiency virus (HIV) medication access for people with HIV (PWH) with low incomes in the United States. We quantified the proportion of viral suppression (VS) that is from ADAP clients for 2015-2022.

methodsFor 2015-2022, we obtained viral load (VL) test results and VS data from publicly available, jurisdiction-level data on ADAP clients and PWH. We report descriptive statistics including the proportion of PWH with a VL who had VS and were supported by ADAPs.

resultsAfter excluding jurisdictions with missing data, PWH who were included in the analysis for each year was 63.7%-96.4%. Viral suppression for PWH each year was 60%-66.3%. Viral suppression for ADAP clients was 81.2%-91.4%. In all years, compared to all PWH, a lower proportion of ADAP clients had a reported VL and a higher proportion had VS. Over 2015-2022, the average proportion of PWH who were ADAP clients was 23.1%, the proportion of PWH with VLs who were ADAP clients was 22.2%, and the proportion of PWH with VS who were ADAP clients was 30.8%.

conclusionsAlmost a third of the entire VS rate was from ADAP clients, despite ADAP serving less than 25% of PWH. A much higher proportion of ADAP clients achieved VS, compared to PWH. AIDS Drug Assistance Programs' impact is not due to ADAP clients being over represented among PWH with reported VLs. AIDS Drug Assistance Program does not directly receive any federal Ending the HIV Epidemic (EHE) Initiative funding. Policymakers should examine how ADAPs can support the EHE Initiative.

Indexed as

Acquired Immunodeficiency SyndromeAnti-HIV AgentsHIV InfectionsViral LoadHumansPovertyUnited StatesAnti-HIV AgentsAIDS drug assistance programsending the HIV epidemicHIVpublic health programviral suppression

Identifiers

PMID41877607
PMCPMC13189682

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.